217 related articles for article (PubMed ID: 27995580)
21. Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma.
Villalobos VM; Mo G; Agulnik M; Pollack SM; Rushing DA; Singh A; Van Tine BA; McNaughton R; Decker RL; Zhang W; Shahir A; Cronier DM
Cancer Med; 2020 Feb; 9(3):882-893. PubMed ID: 31821732
[TBL] [Abstract][Full Text] [Related]
22. Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.
Mo G; Baldwin JR; Luffer-Atlas D; Ilaria RL; Conti I; Heathman M; Cronier DM
Clin Pharmacokinet; 2018 Mar; 57(3):355-365. PubMed ID: 28620891
[TBL] [Abstract][Full Text] [Related]
23. Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model.
Higuchi T; Miyake K; Sugisawa N; Oshiro H; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Lett; 2019 Jun; 451():122-127. PubMed ID: 30867142
[TBL] [Abstract][Full Text] [Related]
24. Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma : Data of real-world utilization in Austria.
Seeber A; Weiss L; Romeder F; Szkandera J; Kuehr T; Kostner S; Pichler P; Jaeger T; Kocher F; Greil R; Brodowicz T
Wien Klin Wochenschr; 2021 Jan; 133(1-2):21-25. PubMed ID: 31620878
[TBL] [Abstract][Full Text] [Related]
25. PDGFRα monoclonal antibody: Assessment of embryo-fetal toxicity and time-dependent placental transfer of a murine surrogate antibody of olaratumab in mice.
Luffer-Atlas D; Reddy VR; Hilbish KG; Grace CE; Breslin WJ
Birth Defects Res; 2018 Nov; 110(18):1358-1371. PubMed ID: 30367709
[TBL] [Abstract][Full Text] [Related]
26. A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors.
Chiorean EG; Sweeney C; Youssoufian H; Qin A; Dontabhaktuni A; Loizos N; Nippgen J; Amato R
Cancer Chemother Pharmacol; 2014 Mar; 73(3):595-604. PubMed ID: 24452395
[TBL] [Abstract][Full Text] [Related]
27. PDGFRA Antibody for Soft Tissue Sarcoma.
Klug LR; Heinrich MC
Cell; 2017 Feb; 168(4):555. PubMed ID: 28187274
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.
Wagner AJ; Kindler H; Gelderblom H; Schöffski P; Bauer S; Hohenberger P; Kopp HG; Lopez-Martin JA; Peeters M; Reichardt P; Qin A; Nippgen J; Ilaria RL; Rutkowski P
Ann Oncol; 2017 Mar; 28(3):541-546. PubMed ID: 28426120
[TBL] [Abstract][Full Text] [Related]
29. Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience.
Striefler JK; Brandes F; Baur A; Pfitzner BM; Kaul D; Rau D; Dörr A; Schmiester M; Koulaxouzidis G; Bullinger L; Märdian S; Flörcken A
BMC Cancer; 2020 Jan; 20(1):68. PubMed ID: 31996176
[TBL] [Abstract][Full Text] [Related]
30. Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma.
Jones RL; Mo G; Baldwin JR; Peterson PM; Ilaria RL; Conti I; Cronier DM; Tap WD
Cancer Chemother Pharmacol; 2019 Jan; 83(1):191-199. PubMed ID: 30406840
[TBL] [Abstract][Full Text] [Related]
31. Olaratumab: A New Strategy in the Treatment of Advanced Soft-Tissue Sarcoma.
Moore DC; Lavery LA
J Adv Pract Oncol; 2018 Mar; 9(2):235-240. PubMed ID: 30588358
[TBL] [Abstract][Full Text] [Related]
32. Revocation of the conditional marketing authorisation of a cancer medicine: The olaratumab experience.
Herold R; Camarero J; Melchiorri D; Sebris Z; Enzmann H; Pignatti F
Eur J Cancer; 2019 Dec; 123():25-27. PubMed ID: 31655357
[No Abstract] [Full Text] [Related]
33. PDGFRα monoclonal antibody: Assessment of toxicity in juvenile mice administered a murine surrogate antibody of olaratumab.
Baracani R; Bhaskaran M; Davis SM; Morford L; Luffer-Atlas D
Birth Defects Res; 2023 Apr; 115(7):782-796. PubMed ID: 36916488
[TBL] [Abstract][Full Text] [Related]
34. A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy.
Liang M; Wang B; Schneider A; Vainshtein I; Roskos L
AAPS J; 2020 Nov; 23(1):4. PubMed ID: 33210183
[TBL] [Abstract][Full Text] [Related]
35. Dupilumab: First Global Approval.
Shirley M
Drugs; 2017 Jul; 77(10):1115-1121. PubMed ID: 28547386
[TBL] [Abstract][Full Text] [Related]
36. Olaratumab for STS Disappoints in Phase III.
Cancer Discov; 2019 Mar; 9(3):312-313. PubMed ID: 30696623
[TBL] [Abstract][Full Text] [Related]
37. Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab.
Pontes C; Zara C; Torrent-Farnell J; Obach M; Nadal C; Vella-Bonanno P; Ermisch M; Simoens S; Hauegen RC; Gulbinovic J; Timoney A; Martin AP; Mueller T; Nachtnebel A; Campbell S; Selke G; Bochenek T; Rothe CC; Mardare I; Bennie M; Fürst J; Malmstrom RE; Godman B
Appl Health Econ Health Policy; 2020 Feb; 18(1):5-16. PubMed ID: 31696433
[TBL] [Abstract][Full Text] [Related]
38. Burosumab: First Global Approval.
Lamb YN
Drugs; 2018 Apr; 78(6):707-714. PubMed ID: 29679282
[TBL] [Abstract][Full Text] [Related]
39. Targeted treatments of sarcomas and connective tumors beside gastrointestinal stromal tumor.
Martin-Broto J; Hindi N
Curr Opin Oncol; 2016 Jul; 28(4):338-44. PubMed ID: 27166665
[TBL] [Abstract][Full Text] [Related]
40. Olaratumab (Lartruvo) for soft-tissue sarcoma.
Med Lett Drugs Ther; 2017 Aug; 59(1527):e138-e139. PubMed ID: 28787747
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]